Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 4/20 | 0.61 |
| ▸ | RARB | P10826 | 1/20 | 0.55 |
| ▸ | RARG | P13631 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.52 |
| ▸ | RXRA | P19793 | 2/20 | 0.50 |
| ▸ | RXRB | P28702 | 2/20 | 0.50 |
| ▸ | RXRG | P48443 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11564114 | 0.98 | SRD5A2 (0.59) | SRD5A2RARBRARGTP53TSHR | |
| SCHEMBL107327 | 0.86 | SRD5A2 (0.61) | SRD5A2RARBRARGTP53TSHR | |
| SCHEMBL28843318 | 0.84 | SRD5A2 (0.57) | SRD5A2EPHX2ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL10013563 | 0.83 | SRD5A2 (0.57) | SRD5A2RARBRARGTP53TSHR | |
| SCHEMBL18130711 | 0.83 | SRD5A2 (0.57) | SRD5A2RARBRARGTP53TSHR | |
| SCHEMBL4861421 | 0.83 | SRD5A2 (0.57) | SRD5A2RARBRARGTP53TSHR | |
| SCHEMBL9178487 | 0.83 | SRD5A2 (0.57) | SRD5A2RARBRARGTP53TSHR | |
| Ethane SCHEMBL10971565 | 0.82 | SRD5A2 (0.80) | SRD5A2RARBRARGTP53TSHR | |
| SCHEMBL18290647 | 0.82 | MAOB (0.49) | EPHX2NR1H4ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL78879 | 0.81 | SRD5A2 (0.87) | SRD5A2TP53TSHREPHX2RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119391247-A | Chip-level super-hydrophobic nano insulation protective coating and preparation method thereof | 中科微新材料(深圳)有限公司 | 2025-02-07 | — | — | CN | claimed |
| CN-113559802-B | Device and method for synthesizing drug intermediate trifluoromethyl substituted aromatic compound | 北京六合宁远医药科技股份有限公司 | 2023-03-17 | — | — | CN | claimed |
| CN-113559802-A | Device and method for synthesizing drug intermediate trifluoromethyl substituted aromatic compound | 北京六合宁远医药科技股份有限公司 | 2021-10-29 | — | — | CN | claimed |
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | disclosed |
| CN-119391247-A | Chip-level super-hydrophobic nano insulation protective coating and preparation method thereof | 中科微新材料(深圳)有限公司 | 2025-02-07 | — | — | CN | disclosed |
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| CN-117582436-A | Iminoacyl hydrazides, compositions containing same and uses thereof | 甫康（上海）健康科技有限责任公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-116836173-B | Iminoacyl hydrazides, compositions containing same and uses thereof | 甫康（上海）健康科技有限责任公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-116836173-A | Iminoacyl hydrazides, compositions containing same and uses thereof | 甫康（上海）健康科技有限责任公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-113559802-B | Device and method for synthesizing drug intermediate trifluoromethyl substituted aromatic compound | 北京六合宁远医药科技股份有限公司 | 2023-03-17 | — | — | CN | disclosed |
| CN-113559802-A | Device and method for synthesizing drug intermediate trifluoromethyl substituted aromatic compound | 北京六合宁远医药科技股份有限公司 | 2021-10-29 | — | — | CN | disclosed |
| EP-2576557-A1 | NOVEL ANTIFUNGAL 5,6-DIHYDRO-4-[(DIFLUOROETHYL)PHENYL]-4H-PYRROLO[1,2-a][1,4]BENZODIAZEPINE AND 4-(DIFLUOROETHYL)PHENYL-6H-PYRROLO[1,2-a][1,4]BENZODIAZEPINE DERIVATIVES | Janssen Pharmaceutica, N.V. (BE) | 2013-04-10 | — | — | EP | disclosed |
| US-20130085136-A1 | NOVEL ANTIFUNGAL 5,6-DIHYDRO-4-[(DIFLUOROETHYL)PHENYL]-4H-PYRROLO[1,2-a][1,4]BENZODIAZEPINE AND 4-(DIFLUOROETHYL)PHENYL-6H-PYRROLO[1,2-a][1,4]BENZODIAZEPINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-04 | — | — | US | disclosed |
| WO-2011154298-A1 | NOVEL ANTIFUNGAL 5,6-DIHYDRO-4-[(DIFLUOROETHYL)PHENYL]-4H-PYRROLO[1,2-a][1,4]BENZODIAZEPINE AND 4-(DIFLUOROETHYL)PHENYL-6H-PYRROLO[1,2-a][1,4]BENZODIAZEPINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-15 | — | — | WO | disclosed |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7504508-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1740547-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005100321-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-4173706-A | REACTING WITH MOLYBDENUM HEXAFLUORIDE | INSTITUTE NATIONAL DE RECHERCHE CHIMIQUE APPLIQUEE (FR) | 1979-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, UBXN1 | SRD5A2 3620/4885RARB 3994/4885RARG 3869/4885 |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | SRD5A2 762/4885RARB 894/4885RARG 879/4885 |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | SRD5A2 762/4885RARB 894/4885RARG 879/4885 |
| US-20130085136-A1 | NOVEL ANTIFUNGAL 5,6-DIHYDRO-4-[(DIFLUOROETHYL)PHENYL]-4H-PYRROLO[1,2-a][1,4]BENZODIAZEPINE AND 4-(DIFLUOROETHYL)PHENYL-6H-PYRROLO[1,2-a][1,4]BENZODIAZEPINE DERIVATIVES | GABBR1, CYP2D6, GABBR2 | SRD5A2 681/4885RARB 2140/4885RARG 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.